A Novel Lineage Specific Metastasis Suppressor Pathway in Lung Cancer

肺癌中一种新的谱系特异性转移抑制途径

基本信息

  • 批准号:
    8436668
  • 负责人:
  • 金额:
    $ 38.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-11 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Thoracic malignancies account for more deaths than prostate, breast and colorectal cancer combined. The most frequently diagnosed lung cancer subtypes is lung adenocarcinoma (ADC), which can metastasize rapidly to multiple vital organs. Despite recent advances in the genetic classification of lung cancers, the molecular and biological determinants of this aggressive clinical course remain unknown. The mammalian lungs are complex organs that require the specification of various epithelial cell types for proper homeostasis. By employing innovative computational and experimental approaches, we uncovered a unique link between differentiation specific gene expression patterns of certain lung epithelial cells and human ADC recurrences. In particular, we discovered a metastasis suppressor pathway associated with the cell fate transcription factors GATA6 and HOPX. We propose that these transcription factors cooperate to restrain multiple biological steps in the metastatic cascade. Moreover, we hypothesize that GATA6 and HOPX control a lineage-specific metastasis program that is selective for epithelial cells of the distal airways and the lug ADC subtype. To study this pathway, we will perform experiments that take advantage of spatio-temporally controlled gene gain or loss of function approaches in vivo. First, we will characterize the biological function(s) of GATA6 and HOPX during tumorigenesis, distant organ metastasis, and lung ADC differentiation using our established in vivo model of metastatic dissemination and colonization by human ADC cells. Second, we will develop a complementary model in genetically engineered mice, to study how loss of Gata6 and/or Hopx cooperates with Kras and p53 mutations at different stages of metastatic progression, and their associated effects on endogenous stem/progenitor cells of the murine airways. Finally, we will integrate multiple approaches to elucidate the downstream mechanism by which the GATA6/HOPX pathway restrains metastatic progression in human ADCs, through the control of their target gene, the Hsa-miR-302/367 cluster. Our project is predicted to reveal conserved epigenetic networks that control lung homeostasis, and how their perturbation endows thoracic cancers with metastatic competence to multiple tissues. The overall goal of our proposal may therefore shed new light into the origins of aggressive metastatic tumors, and provide insights into more accurate diagnostic modalities for lung cancer patients at risk for metastatic disease. PUBLIC HEALTH RELEVANCE: Thoracic malignancies are the principal source of cancer related deaths due to the rapid metastatic spread of lung cancer cells. Our novel multi-disciplinary approach proposes to reveal molecular programs that are specific to certain tissue cell types and which characterize this aggressive clinical course. We believe that this project wil reveal fundamental new principles in pulmonary biology as well as provide therapeutic insight for lung cancer patients at risk of metastatic disease.
描述(由申请人提供):胸部恶性肿瘤导致的死亡人数超过前列腺癌、乳腺癌和结直肠癌的总和。最常诊断的肺癌亚型是肺腺癌(ADC),它可以迅速转移到多个重要器官。尽管最近在肺癌的遗传分类方面取得了进展,但这种侵袭性临床过程的分子和生物学决定因素仍然未知。哺乳动物肺是复杂的器官,其需要各种上皮细胞类型的特化以进行适当的细胞分化。 体内平衡通过采用创新的计算和实验方法,我们发现了某些肺上皮细胞的分化特异性基因表达模式与人类ADC复发之间的独特联系。特别地,我们发现了与细胞命运转录因子GATA 6和HOPX相关的转移抑制途径。我们认为,这些转录因子的合作,以抑制多个生物步骤的转移级联。此外,我们假设GATA 6和HOPX控制一个谱系特异性转移程序,该程序对远端气道和lug ADC亚型的上皮细胞具有选择性。为了研究这一途径,我们将进行实验,利用时空控制的基因获得或功能丧失的方法在体内。首先,我们将描述 GATA 6和HOPX在肿瘤发生、远处器官转移和肺ADC分化过程中的生物学功能,使用我们建立的人ADC细胞转移性播散和定殖的体内模型。其次,我们将在基因工程小鼠中开发一种互补模型,以研究Gata 6和/或Hopx的丢失如何在转移进展的不同阶段与Kras和p53突变合作,以及它们对小鼠气道内源性干/祖细胞的相关影响。最后,我们将整合多种方法来阐明GATA 6/HOPX通路通过控制其靶基因Hsa-miR-302/367簇来抑制人类ADC转移进展的下游机制。我们的项目预计将揭示保守的表观遗传网络,控制肺内稳态,以及他们的扰动如何赋予胸部癌症转移到多种组织的能力。因此,我们提案的总体目标可能为侵袭性转移性肿瘤的起源提供新的线索,并为有转移性疾病风险的肺癌患者提供更准确的诊断方式。 公共卫生关系:由于肺癌细胞的快速转移扩散,胸部恶性肿瘤是癌症相关死亡的主要来源。我们的新的多学科方法建议揭示特定于某些组织细胞类型的分子程序,并表征这种侵略性的临床过程。我们相信,这个项目将揭示肺生物学的基本新原理,并为有转移性疾病风险的肺癌患者提供治疗见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Don X Nguyen其他文献

Don X Nguyen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Don X Nguyen', 18)}}的其他基金

Uncovering the Biology of Resistance to Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Patient-Derived Models.
揭示 EGFR 突变肺癌患者衍生模型中酪氨酸激酶抑制剂耐药性的生物学。
  • 批准号:
    9920134
  • 财政年份:
    2019
  • 资助金额:
    $ 38.54万
  • 项目类别:
Uncovering the Biology of Resistance to Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Patient-Derived Models.
揭示 EGFR 突变肺癌患者衍生模型中酪氨酸激酶抑制剂耐药性的生物学。
  • 批准号:
    10376749
  • 财政年份:
    2019
  • 资助金额:
    $ 38.54万
  • 项目类别:
Uncovering the Biology of Resistance to Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Patient-Derived Models.
揭示 EGFR 突变肺癌患者衍生模型中酪氨酸激酶抑制剂耐药性的生物学。
  • 批准号:
    10616672
  • 财政年份:
    2019
  • 资助金额:
    $ 38.54万
  • 项目类别:
Project 3: Identifying and targeting mediators of CNS metastasis from lung cancer
项目3:识别和靶向肺癌中枢神经系统转移的介质
  • 批准号:
    10203856
  • 财政年份:
    2015
  • 资助金额:
    $ 38.54万
  • 项目类别:
A novel lineage pathway controls metabolic adaptation by metastatic lung cancers
一种新的谱系途径控制转移性肺癌的代谢适应
  • 批准号:
    8984877
  • 财政年份:
    2014
  • 资助金额:
    $ 38.54万
  • 项目类别:
A novel lineage pathway controls metabolic adaptation by metastatic lung cancers
一种新的谱系途径控制转移性肺癌的代谢适应
  • 批准号:
    9182876
  • 财政年份:
    2014
  • 资助金额:
    $ 38.54万
  • 项目类别:
Epigenetic modulation of lung cancer metastasis by a novel long intergenic RNA
新型长基因间RNA对肺癌转移的表观遗传调节
  • 批准号:
    8900254
  • 财政年份:
    2014
  • 资助金额:
    $ 38.54万
  • 项目类别:
A Novel Lineage Specific Metastasis Suppressor Pathway in Lung Cancer
肺癌中一种新的谱系特异性转移抑制途径
  • 批准号:
    8681391
  • 财政年份:
    2012
  • 资助金额:
    $ 38.54万
  • 项目类别:
A NOVEL LINEAGE SPECIFIC METASTASIS PATHWAY IN LUNG CANCER
肺癌中一种新的谱系特异性转移途径
  • 批准号:
    10066312
  • 财政年份:
    2012
  • 资助金额:
    $ 38.54万
  • 项目类别:
A NOVEL LINEAGE SPECIFIC METASTASIS PATHWAY IN LUNG CANCER
肺癌中一种新的谱系特异性转移途径
  • 批准号:
    9884455
  • 财政年份:
    2012
  • 资助金额:
    $ 38.54万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.54万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 38.54万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.54万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.54万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.54万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.54万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.54万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 38.54万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 38.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 38.54万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了